Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.
about
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model.Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.Evaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT).Challenges and opportunities in the advancement of nanomedicines.Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacyTherapeutic nanoparticles in clinics and under clinical evaluation.Clinical advances of nanocarrier-based cancer therapy and diagnostics.An overview of quinoline as a privileged scaffold in cancer drug discovery.Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases.Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive AgentsSupramolecular chemotherapy based on host-guest molecular recognition: a novel strategy in the battle against cancer with a bright future.Silver nanoparticle conjugation affects antiacanthamoebic activities of amphotericin B, nystatin, and fluconazole.
P2860
Q33416097-D023727C-E3EF-4E82-A99E-AC7C230D64A5Q33564844-3F5A4E7F-3561-48C9-A31A-32B460D6F324Q34708283-8D230A76-E972-49EE-B7C8-AAB2E28197AAQ36071814-00A14ADD-65B4-4B5F-A366-C985F65A89EAQ36417295-75DDB71D-99A3-46AE-B526-40E91D00D6DFQ37253857-AFC63FC1-1D5B-41AC-84B0-17526777BCADQ38087986-BFF4724A-EAD9-4633-BE2F-64D9DE99ECF0Q38848965-38FB5DC1-BDCE-4084-A8A8-56A81DEBFCB0Q39235281-1EB7B846-3076-4997-890B-7EF74D3FC885Q39458957-A974D08D-5D84-4743-90D4-BF997F36916EQ41280444-4C0AE6C0-ED84-433D-A61D-22CBA540D3AEQ42755952-91A1198F-0D1D-4E77-887A-6C754E33981BQ47599299-D7F90B5B-E0CC-4EF9-BE6B-9F822FE8CB8CQ47794406-AFF6EB59-CD7D-4DF4-8572-7AEA9AD3C104
P2860
Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Pharmacokinetics and antitumor ...... an colon carcinoma xenografts.
@ast
Pharmacokinetics and antitumor ...... an colon carcinoma xenografts.
@en
Pharmacokinetics and antitumor ...... an colon carcinoma xenografts.
@nl
type
label
Pharmacokinetics and antitumor ...... an colon carcinoma xenografts.
@ast
Pharmacokinetics and antitumor ...... an colon carcinoma xenografts.
@en
Pharmacokinetics and antitumor ...... an colon carcinoma xenografts.
@nl
prefLabel
Pharmacokinetics and antitumor ...... an colon carcinoma xenografts.
@ast
Pharmacokinetics and antitumor ...... an colon carcinoma xenografts.
@en
Pharmacokinetics and antitumor ...... an colon carcinoma xenografts.
@nl
P2093
P1476
Pharmacokinetics and antitumor ...... an colon carcinoma xenografts.
@en
P2093
Alex V Yurkovetskiy
Carolina B Cabral
Jeremy Sen
Mark D Walsh
Robert J Fram
Sumit Rawal
Suzan K Hanna
Timothy B Lowinger
William C Zamboni
P304
P356
10.1158/1078-0432.CCR-11-1554
P407
P577
2012-03-05T00:00:00Z